P114. The clinical impact and resource implication of her-2 testing in breast cancer patients 80 and over: A multi-centre retrospective study

Abstract

Background: Current guidelines state that all patients diagnosed with invasive breast cancer should have full receptor profile performed to guide optimal management. While it is vital to offer patients personalised treatment, tests should only be performed if they will impact management. Adjuvant systemic therapy and in particular anti-HER-2 therapies such as Trastuzumab, however have significant toxicities and are less likely to be offered in older patients many of whom have other co-morbidities. We aimed to explore the incidence of HER-2 positivity in patients aged 80 and over to determine the proportion of these in whom testing influenced management. The resource implications of HER-2 testing in this group was also assessed.